Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
ESR1 mutations were absent in PT tissue samples and were detected only in metastases obtained after CTC characterization.
|
31669227 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Recent investigations of ER imaging with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) have focused on diagnosing ER+ metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit.
|
31732674 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis.
|
31204155 |
2020 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of carbonic anhydrase XII (CA12) is associated with the expression of estrogen receptor alpha (ERα) in breast cancer and is linked to a good prognosis with a lower risk of metastasis.
|
31636386 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.
|
30511377 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The first tumors of sCBC were more likely to have higher stage and more lymph and distant metastases, whereas those of mCBC were more often infiltrating ductal carcinoma (IDC), had localized stage, were estrogen receptor (ER) and progesterone receptor (PR) negative, and had less axillary nodal involvement.
|
31281731 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The distinct membrane-immunopositivity was correlated with high HG, severe nuclear pleomorphism, frequent mitotic counts, high Ki-67 labeling index, HER2/neu overexpression, and low estrogen receptor status (P < 0.05), but not with tubular formation, pT categories, node metastasis, vessel permeation, and pStage.
|
31728728 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Approximately 30% of ERα breast cancer patients relapse with metastatic disease following adjuvant endocrine therapies.
|
31073170 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Furthermore, ESR1 mutations express a unique transcriptional profile that favors tumor progression, suggesting that selected ESR1 mutations may influence metastasis.
|
31318440 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Association of <i>ESR1</i> Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil.
|
31511774 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This feasibility study showed that <sup>18</sup>[F]-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) could accurately predict nodal response after neoadjuvant chemotherapy (NAC) among patients with breast cancer with initial nodal metastasis except in estrogen receptor-negative, human epidermal growth factor receptor 2-positive subtype.
|
31826976 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Multivariable Cox proportional hazards analysis showed that a higher ADC difference value (>0.698 × 10<sup>-3</sup> mm<sup>2</sup>/sec) (hazard ratio [HR], 4.5; 95% confidence interval [CI]: 2.0, 10.0; <i>P</i> < .001), presence of axillary node metastasis (HR, 3.3; 95% CI: 1.2, 9.3; <i>P</i> = .02), and estrogen receptor negativity (HR, 2.6; 95% CI: 1.2, 5.7; <i>P</i> = .02) were associated with poorer distant metastasis-free survival.
|
30860453 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The aim of the present study was to analyze metastasized breast cancer (BC) patients with regard to the discordance of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2).
|
31092464 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
MiR-22 downregulated the expression of NK1R-Tr and ERα to delay and weaken phosphorylation of ERK1/2 to inhibit proliferation and metastasis of breast cancer cells.
|
30502362 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A 72-year-old woman with estrogen receptor-negative human epidermal growth factor 2-positive breast cancer with distant metastases in the lung was admitted.
|
31842789 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
But the exact molecular mechanism of ERα-36 and STAT3 on metastasis is still not fully understood.
|
31409371 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Whereas ESR1 alterations are enriched in the metastases of both ILC and IDC compared with breast specimens, NF1 alterations are enriched only in ILC metastases (mILC).
|
30423024 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Using both GATA3 and SOX10 is recommended for confirming breast as the site of origin in metastases that lack estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, whereas the addition of AR is not helpful.
|
30468800 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Increased leptin, which upregulates estrogen receptor alpha (ERα) and aromatase, enhances estrogen bioavailability and signaling in estrogen receptor positive (ER⁺) breast cancer (BC) tumor growth and metastasis.
|
30897853 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In addition, STC2 gene probably promotes the development and metastasis of breast cancer by interacting with estrogen and ER, and it may become a new direction for breast cancer endocrine therapy.
|
31845230 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, the double-positive expression of immunoreactive estrogen receptor (ER) β and p53 proteins is closely associated with the incidence of metastasis and/or recurrence.
|
31689961 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Melatonin mitigates cancer initiation, progression and metastasis through inhibition of both the synthesis of estrogens and the transcriptional activity of the estradiol-ER (Estrogen receptor) complex in the estrogen-dependent breast cancer cell line MCF-7.
|
31331001 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group).
|
30675282 |
2019 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
These questions have provoked new mechanistic hypotheses that link resistance to endocrine agents to: (1) Specific defects in single strand break repair are associated with increased mortality from ER+ breast cancer [1,2]; (2) Loss/mutations of certain single strand break repair proteins that disrupt estrogen-regulated cell cycle control through the ATM, CHK2, CDK4 axis [1,2] thereby directly coupling endocrine therapy resistance to specific DNA repair defects; (3) Acquired mutations that drive metastasis include the generation of in-frame ESR1 gene fusions that activate epithelial-to-mesenchymal transition (EMT) driven metastasis as well as endocrine drug-resistant proliferation [3].
|
31839155 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Because estrogen receptor-α (ERα) is expressed in ~70% of patients, therapeutic intervention by ERα-targeted endocrine therapies remains the leading strategy to prevent progression and/or metastasis in the adjuvant setting.
|
30753408 |
2019 |